ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,770.20
0.55%
US Tech 100
19,636.04
0.55%
다우존스 지수
42,801.72
0.52%
Bitcoin
83,174.45
-3.46%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Amneal Pharmaceuticals Inc (AMRX)

  7. Amneal Pharmaceuticals Inc (AMRX) 뉴스

AMRX

Amneal Pharmaceuticals (AMRX)

Amneal Pharmaceuticals Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:AMRX
일자시간출처헤드라인심볼기업
2025/03/0806:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/03/0610:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/03/0609:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/03/0609:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/03/0609:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/03/0609:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/03/0607:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/03/0606:57Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/03/0508:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/02/2820:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/02/2820:00Business WireAmneal Reports Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/02/1922:00Business WireAmneal Launches Mesalamine and Receives U.S. FDA Approval for LenalidomideNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/02/0606:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/01/2922:30Business WireAmneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025NASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/01/2407:49Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/01/2322:00Business WireAmneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for RifaximinNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/01/1520:14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/01/1106:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/01/0706:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2025/01/0306:48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2024/12/0422:00Business WireAmneal to Participate at Upcoming Investor ConferencesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2024/11/2706:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2024/11/2606:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2024/11/2306:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2024/11/2300:39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2024/11/2206:05Business WireAmneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 AgonistNASDAQ:AMRXAmneal Pharmaceuticals Inc
2024/11/2204:01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2024/11/2006:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2024/11/1603:49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AMRXAmneal Pharmaceuticals Inc
2024/11/1506:11Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AMRXAmneal Pharmaceuticals Inc
 검색 관련기사 보기:NASDAQ:AMRX

최근 히스토리

NASDAQ
AMRX
Amneal Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지